Esperion Therapeutics (ESPR) Tops Q4 EPS by 9c

Esperion Therapeutics (NASDAQ: ESPR) reported Q4 EPS of ($0.76), $0.09 better than the analyst estimate of ($0.85). Revenue for the quarter came in at $18.18 million versus the consensus estimate of $20.57 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Ennis (EBF) Reports In-Line Q1 EPS
• Hermès can regain momentum despite China weakness, Jefferies says